

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2015

RESTORGENEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-24477
(Commission File
Number)

30-0645032
(I.R.S. Employer
Identification No.)

2150 East Lake Cook Road, Suite 750
Buffalo Grove, Illinois
(Address of principal executive offices)

60089
(Zip Code)

(847) 777-8092
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2015, RestorGenex Corporation (the “Company”) issued a news release announcing its consolidated financial results for the nine months ended September 30, 2015. The full text of the news release is set forth in Exhibit 99.1 attached hereto and is incorporated by reference in this current report on Form 8-K as if fully set forth herein.

The Company is furnishing the information contained in this report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission. This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

<u>Exhibit No.</u>	<u>Description</u>
99.1	News release announcing consolidated financial results for the nine months ended September 30, 2015 issued by RestorGenex Corporation on November 12, 2015 (furnished herewith)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2015

RESTORGENEX CORPORATION

By: /s/ Phillip B. Donenberg
Name: Phillip B. Donenberg
Title: Chief Financial Officer and Secretary

**RESTORGENEX CORPORATION
CURRENT REPORT ON FORM 8-K**

EXHIBIT INDEX

Exhibit No.	Description	Method of Filing
99.1	News release announcing consolidated financial results for the nine months ended September 30, 2015 issued by RestorGenex Corporation on November 12, 2015	Furnished herewith



FOR IMMEDIATE RELEASE

OTCQX: RESX

**RestorGenex Reports
Third Quarter 2015 Financial Results**

Buffalo Grove, Illinois (November 12, 2015) - RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and financial results for the nine months ended September 30, 2015.

As of September 30, 2015, cash and cash equivalents totaled approximately \$14.6 million, which the Company believes is sufficient to fund its operations into the second half of 2016. The Company has no debt. RestorGenex incurred a net loss of \$20.7 million for the nine months ended September 30, 2015, or \$1.11 per share, compared to net loss of \$9.3 million, or \$0.76 per share, for the nine months ended September 30, 2014. The primary reason for the increase in net loss was an \$11.1 million non-cash impairment of goodwill during the nine months ended September 30, 2015.

The Company intends to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 within the next few days.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. In addition, as a part of the Company's corporate strategy, it continues to seek, consider and if appropriate to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.

For additional information please see: www.restorgenex.com.

Contact: Info@restorgenex.com